Lipella receives Nasdaq delisting notice for equity deficiency; hearing set for Dec 12

LIPELLA PHARMACEUTICALS INC.

Nasdaq notified Lipella of delisting for stockholders' equity of $1.7M, below $2.5M minimum.
Company appealed by Oct 23, 2024; hearing before Nasdaq Hearings Panel set for Dec 12, 2024.
Trading suspension stayed pending hearing; stock continues trading on Nasdaq during appeal.
Bid price non-compliance also outstanding; reverse split approved to address minimum bid requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.